Delhi-based pharma major Mankind Pharma delivered impressive financial results for Q4FY26, with consolidated net profit surging 32% year-on-year to ₹554 crore compared to ₹421 crore in the same quarter last year. According to latest stock exchange notification, the company's revenue from operations grew 11.8% Y-o-Y to ₹3,443 crore from ₹3,079 crore in Q4 FY25, beating analyst estimates. The strong performance was primarily driven by robust demand for chronic therapies and over-the-counter healthcare products, with the company reporting its second consecutive quarter of profit growth after declining for four quarters. Operating income (EBITDA) rose 36.1% to ₹930 crore from ₹683 crore in the corresponding quarter, with EBITDA margin expanding significantly to 27% from 22.2% year-on-year, demonstrating improved operational efficiency.
The company's domestic segment, which contributes 85% to overall revenue, demonstrated strong momentum with growth of 13.4% to ₹2,886 crore in the March quarter, though this was down 5% sequentially. As reported by Informist Media, this growth was led by strong demand for drugs in chronic therapies including cardiac and anti-diabetes segments. Mankind's chronic therapy share increased by 120 basis points year-on-year to around 40% in Q4 FY26, with cardiac segment growing 14.7% and anti-diabetes segment expanding 11.6%. However, the company's secondary sales growth of 8.7% underperformed the Indian pharmaceutical market, which grew at over 10%.
The company's over-the-counter consumer healthcare business recorded strong 20% year-on-year growth to ₹2.13 billion, driven by healthy sales of established brands including Manforce, Prega News, Gas-O-Fast and Nimulid. According to Informist Media, this performance was supported by strong growth in the Bharat Serums and Vaccines speciality business, with healthy growth in secondary sales for Gas-o-fast, PregaNews, and Ova news. The Consumer Healthcare business contributed significantly to the overall revenue growth and reflects the company's diversified product portfolio strength.
International revenue showed modest growth of 4% year-on-year to ₹5.57 billion due to geopolitical headwinds affecting global markets. As reported by Informist Media, the muted international performance contrasted with the strong domestic and OTC business growth, highlighting the company's dependence on domestic markets for revenue generation. The company's revenues from exports were slightly higher year-on-year despite the challenging global environment.
The company announced significant strategic developments including the reappointment of Satish Kumar Sharma as whole-time director for five years and a planned investment of ₹500 crore in subsidiary Mankind Medicare Pvt. Ltd. for capacity expansion and setting up a new plant. According to latest reports, the board also approved an additional investment of ₹500 crore in Mankind Medicare, demonstrating the company's commitment to expanding its manufacturing capabilities. The company also launched four new products in the US market during FY26, taking the total number of products launched to 48.
Despite beating analyst estimates, Mankind Pharma shares closed slightly lower at ₹2,492.60 on the National Stock Exchange on Tuesday, falling 0.12% compared to a 0.14% decline in the NSE Nifty 50 index. According to NDTV Profit, the stock fell as much as 1.03% to ₹2,470 per share during the day. The stock has fallen 2.79% in the last 12 months but risen 13.48% year-to-date, reflecting mixed investor sentiment despite strong quarterly results. The earnings announcement was made after market hours, which may have contributed to the muted market response to the positive financial results.
